PHARMACEUTICAL COMPANY AstraZeneca will pay $1.1bn to resolve an ongoing transfer pricing dispute over its US business.
The UK-Swedish based firm will pay the $1.1bn net costs to US tax authorities to cover transfer pricing arrangements over a 13-year period from 2002 to the end of 2014, it announced today. It had already announced in February that it will pay £505m to settle a dispute with HM Revenue & Customs.
“AstraZeneca had provided in its accounts for the outcome of these issues, at the heart of which are complex transfer pricing considerations that have taken many years to resolve,” the group said.
It also said that the group’s effective tax rate for 2011 is expected to be approximately six percentage points lower than the previous guidance of 27%, at around 21%.
Freelancers and micro-businesses still need more information about the government’s plans to make tax digital
New dividend tax is an attack on small business owners and is acting against the best interests of the UK economy, warns Top 50 accountants, Bishop Fleming
The Treasury is consulting on how businesses remunerate their staff to assess whether companies are artificially using benefits in kind to avoid tax
HMRC is consulting on proposals to clarify the tax treatments of general and limited partnerships